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Abstract
Background: The aim of this study was to assess the responsiveness of the asthma control test (ACT) to detect
changes at the initiation of therapy and its utilization in the initiation of asthma treatment.
Methods: This study was designed as a randomized clinical trial conducted in a primary care setting. The subjects
were asthma patients who had not received controller therapy for at least two months. The patients were
randomized into two groups: The Saudi Initiative for Asthma (SINA) group and the Global Initiative for Asthma
(GINA) group. Treatment in the SINA group was initiated at step1 when the ACT scores ≥ 20, step 2 when the
score between16-19, and step 3 when the score < 16 began at step 3. The GINA group patients were started on
step 2 when they had persistent asthma symptoms or step 3 when they had severely uncontrolled disease.
Results: Forty-five patients were analyzed in each group. The improvement in ACT score after treatment initiation
was significantly higher when the SINA approach was used (2.9 in the SINA group compared to 1.7 in the GINA
group (p = 0.04)). The improvement in FEV1 was 5.8% in the SINA group compared to 3.4% in the GINA group (p
= 0.46). The number of patients who achieved asthma control at the follow-up visit and required no treatment
adjustment was 33 (73.3%) in the SINA group and 27 (60%) in the GINA group (p = 0.0125).
Conclusion: The ACT was responsive to change at the initiation of asthma treatment and was useful for the
initiation of asthma treatment.
Trial Registration number: ISRCTN31998214
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Background
The Global Initiative for Asthma (GINA) has evolved
management from being based on a severity index to
the concept of achieving asthma control [1-4]. It has
adopted a five-step approach to control asthma, where
each step represents a different treatment option with
increasing efficacy. The five-step approach is designed
to maintain control with the least amount of medication
[1,5]. For the initiation of treatment, the GINA recom-
mended step 2 for most treatment naïve patients with
persistent symptoms, while step 3 was recommended for
severely uncontrolled disease [1]. The National Asthma
Education and Prevention Program (NAEPP) is another
major guideline that utilized asthma severity categoriza-
tion when initiating treatment in treatment-naïve
patients or in those with newly diagnosed asthma [6].
These different approaches were based on a consensus
of experts’ opinions, as there was insufficient available
evidence.
The Saudi Initiative for Asthma management (SINA)
was created by the Saudi Thoracic Society which was
adopted and customized from the GINA, the NAEPP,
and the available local literature [7,8]. The SINA panel
has reached a consensus of using the Asthma Control
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Test (ACT) score to simplify the initiation and adjust-
ment of asthma therapy, as there are variations in the
qualifications of health professionals dealing with
asthma [6]. The ACT is a validated, short, easy to use,
and self-administered instrument used to assess asthma
control [8]. It consists of five items that cover a patient’s
activity limitations, shortness of breath, frequency of
night symptoms, use of rescue medication and a rating
of overall control of the disease over the past 4 weeks
[9,10]. The score of the ACT is the sum of five ques-
tions, where each is scored from 1 (worst) to 5 (best),
leading to a maximum best score of 25. A score ≥ 20
indicates controlled asthma, scores from 16 to 19 indi-
cate partly controlled asthma, and scores < 16 indicate
uncontrolled asthma [11]. In addition to its availability
in Arabic, it is a valuable tool that is responsive to
changes in patient clinical status over time when used
for treatment maintenance and adjustment [6,8,12-14].
Therefore, the objective of this study was to assess the
utilization and responsiveness of the ACT at the initia-
tion of asthma therapy in a primary care setting.
Methods
This study was a randomized clinical trial conducted in
asthma patients who presented at primary care centers
belongs King Abdulaziz Medical City, Riyadh, Saudi
Arabia between 21 September and 12 November 2011.
These primary care centers were operated independent
of the main hospital and open to patients who has med-
ical records at the center. The inclusion criteria included
the following: an age above 12 years, a diagnosis of
asthma, and literacy, as patients had to answer the ACT
without assistance. Patients were excluded if they had
used controller therapy for the two months prior to the
initial presentation in order to ensure that our findings
are contaminated by a prior controller treatment. Con-
troller therapy was defined as the use of inhaled corti-
costeroids, leukotriene modifiers, and/or long-acting
bronchodilators agents. This study was approved by the
Institutional Review Board of the King Abdullah Inter-
national Center for Medical Research (RC10-091). It was
also registered in the International Standard Rando-
mized Controlled Trial Number Register with the num-
ber ISRCTN31998214.
Intervention
Patients were randomized to receive their initial treat-
ment based on either the SINA approach (Group A, Fig-
ure 1) or the GINA approach (Group B). More
specifically, block randomization was carried out with a
block size of 4. To avoid selection bias, the random
numbers generated were kept in closed opaque envel-
opes to assure allocation concealment. Following obtain-
ing the written consent from each patient for
participation in this study, a research nurse collected
each patient’s data, which included basic vital signs, a
baseline spirometer reading, ACT score and basic demo-
graphic data (disease duration, education level, respira-
tory symptoms, exacerbation and hospital admissions,
smoking history, and pulmonary function tests). Peak
expiratory flow (PEF) was obtained at the initial and fol-
low-up visits [15]. The measurement of forced expira-
tory volume in one second (FEV1) was performed by a
spirometer, as per American Thoracic Society standards
[16]. Primary care physicians attended a half-day work-
shop presented by the authors (MA and AA) on SINA
or GINA approaches. An Arabic version of the ACT has
been used which was available from the ACT website
[14,17,18]. Patients who were assigned to the SINA
approach received their initial treatment based on their
ACT score [6]. Patients with an ACT score ≥ 20 started
with step 1, patients with ACT scores 16-19 started
with step 2, and patient with scores less than 16 started
with step 3. Patients allocated to group B commenced
with step 2 based on the GINA recommendations for
persistent asthma symptoms or step 3 when they had
severely uncontrolled disease [1]. The physicians of the
patients allocated to the GINA approach were blinded
to the result of the ACT results. Both guidelines recom-
mended short-acting beta 2 agonists for step 1 and low-
dose inhaled steroids for step 2. Although both guide-
lines recommended the introduction of LABA at step 3,
there was a difference in the dose of inhaled steroids
where the GINA recommended a low dose of inhaled
Figure 1 Initiation of therapy based on the Saudi Initiative for
Asthma.
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steroids and SINA recommended a low-medium dose of
inhaled steroids. Therefore, to avoid any variation, step
3 was unified to be the combination of LABA with low
dose inhaled steroids for both groups. Patients received
an educational session for their asthma that included an
explanation of the nature of the disease, the importance
of compliance, the features of an asthma attack, and
inhaler technique. A follow-up visit was offered to the
patients four weeks later to assess their level of asthma
control using the aforementioned ACT score, and treat-
ments were adjusted accordingly [1,6]. Patients were
advised to return to their physicians between visits if
they felt that their asthma was not under control.
Outcome
The primary outcome was measured by changes in the
mean FEV1, PEF, and ACT scores. More specifically, the
proportion of controlled patients in each of the two
arms was compared. Any treatment adjustments were
also noted at the follow-up visit.
Sample size and statistical analyses
Sample size calculation, we estimated the controlled
patients to be 30% and thus, a sample size of 45 is
needed in each arm to have an 80% power to detect a
difference of 30%, at an alpha level of 0.05. The data
were entered into a Microsoft Excel spreadsheet, which
was then transferred into the Statistical Package for
Social Sciences (SPSS) program, which was used for
data cleaning, management, and analyses. The difference
in outcome between the first visit and the follow-up
visit was calculated, and then patients with a significant
response were flagged. Descriptive analyses were carried
out by calculating the number and percent for categori-
cal variables and mean and standard deviation for con-
tinuous data. The inferential statistics for the
comparison between the two groups was carried out
using the Chi-square test for categorical variables, and
the t-test for continuous variables. The association
between the changes in the different measures consid-
ered (FEV1, PEF, and ACT) between baseline visit and
follow-up visit was done by calculating the Pearson cor-
relation coefficient. A p-value less than or equal to 0.05
was accepted as statistically significant. All randomized
patients were included in the analysis, as per the inten-
tion-to-treat principle.
Results
Ninety-eight patients were recruited for this study (Fig-
ure 2). Forty-five patients in each of the two groups
(SINA and GINA) completed the study and were ana-
lyzed. The baseline characteristics of the two groups
were comparable (Table 1). Although the initial PFM
and FEV1 values were lower in the SINA group than the
GINA group, this difference did not reach statistical sig-
nificance. Table 2 shows the treatment responses of
patients assigned to each group. Although there was
more improvement in the mean FEV1 score of the SINA
group (5.8%) than the GINA group (3.4%), this differ-
ence did not reach statistical significance (p = 0.46). In
contrast, the improvement in PEF was higher in the
GINA group compared to the SINA group, but this dif-
ference also did not reach statistical significance (p =
0.803). The improvement in the ACT score after treat-
ment initiation was significantly higher in the SINA
group compared to the GINA group (2.9 compared to
1.7 (p = 0.04)).
Although both groups showed similarities in categori-
zation based on the initial ACT scores (table 1), the fol-
low-up visit revealed that the SINA group contained 32
controlled asthmatics (71.1%), 9 partially controlled
asthmatics (20.0%), and 4 uncontrolled asthmatics
(31.1%), while the GINA group contained 26 controlled
asthmatics (57.8%), 14 partially controlled asthmatics
(31.1%), and 5 uncontrolled asthmatics (11.1%) (p =
0.185). The correlation between the difference in FEV1
and that of the ACT scores between the initial and fol-
low-up visits was found to be statistically significant,
with a correlation coefficient of 0.21 (p = 0.05).
Although there was a positive correlation between the
changes in FEV1 and PFM (correlation coefficient =
0.19), the change was not significant (p = 0.07). Finally,
there was a very weak positive correlation between the
changes in the PFM and ACT (correlation coefficient =
0.06, p = 0.6).
Figure 3 showed steps adjustments for patients
assigned to either approach. There were 33 (73.3%)
patients in the SINA group who achieved control at the
follow-up visit and required no treatment adjustment,
compared to 27 (60%) in the GINA group (p = 0.0125).
Eight (17.8%) patients in the SINA group required a
Figure 2 Enrollment and allocation of patients in the study.
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step down in therapy, and 4 required a step up in treat-
ment at the follow-up visit. In comparison, 18 patients
in the GINA group required a step down, while no
patients required a step up.
Discussion
This study showed that the ACT was responsive to
changes at the initiation of asthma treatment [6]. It has
also showed the usefulness of the ACT score for the
initiation of asthma treatment compared to the GINA
approach. Despite ample amount of evidence that sup-
ports the use of the ACT for treatment adjustment, a
unique feature of this study is the presentation of new
evidence supporting the utilization of the ACT in mak-
ing an initial asthma treatment decision. The initiation
of asthma treatment has evolved from being based on
severity index to achieving asthma control by
recommending step 2 for most treatment naïve patients
with persistent symptoms and step 3 for severely uncon-
trolled disease. Both the GINA and the NAEPP
approaches require the cumulative experience of health-
care practitioners to make the appropriate clinical judg-
ment. While the severity index and the ACT both use
common items related to asthma symptoms, such as
nocturnal symptoms, the use of reliever inhalers and the
effect of asthma on daily activities, in their classification
strategies, the ACT lacks any pulmonary function mea-
surement. On the other hand, a unique characteristic of
the ACT is the adoption of a simple 5-item Likert scale
that is different from the complex scale adopted in the
severity index. Therefore, there are similarities in the
items covered in the two instruments, but a lack of pul-
monary function measurement in the ACT. The ACT
was utilized in this study because it is a standardized
Table 1 Baseline characteristics for the Saudi Initiative for Asthma group and the Global Initiative for Asthma group
Characteristics SINAa group GINAb group p value
Number of patients 45 45
Age, years (± SD) 42.9 (± 13.4) 42.3 (± 12.6) 0.840
Gender
- Male, No. (%) 14 (31.1%) 19 (42.2%) 0.274
- Female, No. (%) 31 (68.9%) 26 (57.8%)
Body mass index, No. (± SD) 32.6 (± 7.4) 34.0 (± 7.3) 0.370
Disease duration, years (± SD) 10.9 (± 9.3) 10.1 (± 8.6) 0.630
Respiratory Symptoms
- Cough, No. (%) 27 (60.0%) 22 (48.9%) 0.290
- Shortness of breath, No. (%) 10 (22.2%) 15 (33.3%) 0.239
- Wheezing, No. (%) 7 (15.6%) 9 (20.0%) 0.581
Asthma attacks in the past 4 weeks, No. (%) 1.5 (± 1.1) 1.8 (± 1.5) 0.378
Initial visit Peak Flow meter, value (± SD) (L/min) 343.1 (± 129.5) 362.9 (± 148.8) 0.143
Initial visit Forced Expiratory volume in 1 second, Percentage of normal (± SD) 81.4% (± 17.1) 84.3% (± 16.2) 0.269
Initial visit asthma control test score, score (± SD) 17.6 (± 4.5) 17.8 (± 3.6) 0.776
a SINA: Saudi Initiative for Asthma; b GINA: Global Initiative for Asthma
Table 2 Performance of patients assigned to either the Saudi initiative for asthma or Global initiative for asthma
approaches after treatment initiation
Characteristics SINAa group GINAb group p-value
Forced expiratory volume in 1 second
- First visit–No. (± SD) 81.4% (± 17.1%) 84.3% (± 16.2%) 0.269
- Follow-up visit–No. (± SD) 87.2 (± 14.7%) 87.7 (± 17.6) 0.697
- Difference between two visits–No. (± SD) 5.8% (± 12.8) 3.4% (± 13.9) 0.46
Peak flow meter
- First visit–No. (± SD) 343.1 (± 129.3) 362.9 (± 148.8) 0.503
- Follow-up visit–No. (± SD) 389 (± 120.5) 423.1 (± 116.6) 0.182
- Difference between two visits–No. (± SD) 46.84 (63.3%) 60.7 (± 77.8) 0.803
Asthma control test score
- First visit–No. (± SD) 17.6 (± 4.5) 17.8 (± 3.6) 0.776
- Follow-up visit–No. (± SD) 20.5 (± 3.5) 19.5 (± 3.3) 0.43
- Difference between two visits–No. (± SD) 2.9 (± 3.1) 1.7 (± 2.9) 0.04
a SINA: Saudi Initiative for Asthma; b GINA: Global Initiative for Asthma
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objective tool that avoids the variability in the practi-
tioner’s experience and qualifications. It has also been
utilized by both the SINA and the GINA and validated
in the Arabic language [10,13]. Due to the lack of any
other validated gold-standard tool for asthma treatment
initiation, the GINA approach was included in the study
protocol as a benchmark. Moreover, the GINA has
received increasing global acceptance as a guideline for
asthma management.
Utilizing the initial ACT score to determine the
appropriate treatment in this study has led to an
improvement of 2.9 units, better than the 1.7 unit
improvement observed when treatment was determined
by physician judgment based on the GINA approach (p
= 0.04). Though the improvement in FEV1 was better in
the patients who followed the SINA approach, this dif-
ference did not reach statistical significance. This lack of
statistical significance could be related to an inadequate
sample size to assess a positive response of this out-
come. The conflicting results obtained regarding the
improvement in PEF in the GINA group may be related
to the poor correlation of PEF with the ACT and pul-
monary function when used to assess asthma control
[19,20]. An interesting study from Greece utilized the
ACT to assess disease control after treatment initiation
in naïve patients, showed an average response of 1.73
units, which is similar to the response we observed in
the group that used the GINA standards [21]. The
uncontrolled asthma status present in the previous
study based on initial ACT was found to be statistically
correlated with a higher fractional exhaled nitric oxide
(FeNO) and positively correlated with pre-bronchodila-
tor FEV1. Moreover, the change in the ACT between
the two visits was significantly correlated with the
change in the FEV1 and FeNO in that study [22]. The
scanty data regarding the correlation of the ACT with
different parameters at the initiation of treatment are
supported by studies regarding the utilization of the
ACT to assess asthma control. Recent studies have also
shown that a score of less than 19 on the ACT has a
66% sensitivity in detecting uncontrolled asthma and
serves as an objective measure of control that correlates
well with the GINA [22-24]. Another study from Hong
Kong showed that an ACT score ≤ 20 correlated better
with treatment decision than PEF and FeNO. Their find-
ing revealed a sensitivity of 70.5% and specificity of
76.0% [20]. Although FEV1 is the main objective physio-
logical measurement of asthma control, the ACT was
also found to correlate well with lung function and
inflammation [20,25]. Moreover, the ACT was found to
be a useful tool for detecting poorly controlled asthma
to optimize asthma control [26]. These studies have
shown that the ACT was at least equivalent to pulmon-
ary function or FeNO in assessing asthma control or
making a treatment adjustment. This has a practical
implication for treatment adjustment due to the unavail-
ability of spirometry or FeNO in primary care settings,
especially in developing countries.
We observed a non-significant trend toward achieving
control upon follow-up when the ACT was utilized to
determine a treatment plan. Nevertheless, the SINA
group patients showed significant stability in treatment
plan upon follow-up when compared to the GINA
group patients (73.3% vs. 60%). This was supported by
the fact that 40% of those treated with the GINA
approach required a step down in treatment upon fol-
low-up, compared to 17.8% of those who treated with
the SINA approach. Commencing treatment with the
appropriate dose would enhance compliance and mini-
mize the side effects of medications. On the other hand,
8.9% of the patients who followed the SINA required a
step-up in treatment compared to none in the GINA
group, a finding that may indicate an inadequate initial
treatment.
Finally, it is worth mentioning a few limitations and
concerns related to this study. The utilization of the
ACT as an objective measure for initiating asthma ther-
apy is independent of the practitioners’ clinical judg-
ment. In contrast, the knowledge of those practitioners
who utilized the GINA approach in this study may have
been augmented by the pre-study workshop, possibly
contaminating the results in that group. This issue was
discussed during the preparation of the study protocol,
and the authors felt that it was inappropriate to deny
the practitioners’ placement in the GINA arm due to
ethical considerations. In day-to-day practice, most prac-
titioners have variability in their knowledge and experi-
ence and may not have the opportunity for dedicated
education sessions. Therefore, it is an area for future
research to challenge our findings in general practice.
Another limitation was the use of set ACT score limits
Figure 3 Follow-up visit step adjustments for patients assigned
to either the Saudi initiative for asthma or Global initiative for
asthma approaches.
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of 16 and 19 for decisions regarding the appropriate
initial treatment step. Due to the lack of evidence identi-
fying ACT reference scores for treatment initiation,
these numbers were extrapolated from studies that
assessed asthma control to make decisions about treat-
ment adjustment and maintenance. Defining the ACT
categories that determine initial treatment is another
area that needs to be challenged to support its suitability
[25,27].
Conclusions
We believe that despite the aforementioned limitations
and concerns, this study can be considered a pilot pro-
ject that showed the ACT to be responsive to change at
treatment initiation and showed usefulness for the
initiation of asthma treatment compared to the GINA
approach.
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